hydroxyurea has been researched along with Body Weight in 41 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " As an ancillary study carried out during the recently completed Multicenter Study of Hydroxyurea, we examined the effect of hydroxyurea on the body weight, body composition and exercise capacity of adult patients with sickle-cell anaemia." | 9.08 | Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. ( Busby, M; Gulledge, TP; Hackney, AC; Hezier, W; Hoffman, E; Jones, S; Orringer, EP; Strayhorn, D, 1997) |
| " As an ancillary study carried out during the recently completed Multicenter Study of Hydroxyurea, we examined the effect of hydroxyurea on the body weight, body composition and exercise capacity of adult patients with sickle-cell anaemia." | 5.08 | Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. ( Busby, M; Gulledge, TP; Hackney, AC; Hezier, W; Hoffman, E; Jones, S; Orringer, EP; Strayhorn, D, 1997) |
| "Influence of hydroxyurea (HU) on the antitumor effect of irinotecan hydrochloride (CPT-11) was investigated in ICR male mice transplanted with sarcoma 180 cells (S-180)." | 3.72 | Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time. ( Akagi, T; Higuchi, S; Inoue, K; Ishizaki, T; Kage, Y; Makinosumi, T; Ohdo, S; Taguchi, Y; Ushinohama, K; Yamauchi, A; Yukawa, E, 2003) |
| "Rats whose mothers received hydroxyurea (HU, 1 or 2 g/kg) at 14 days of gestation had a 30% deficit in both brain and body weight at birth, when compared with controls." | 3.65 | Maze learning by adult rats after inhibition of neuronal multiplication in utero. ( Adlard, BP; Dobbing, J, 1975) |
| " Results from a single-center trial of individualized, PK-guided dosing of hydroxyurea for children with SCD suggest that individualized dosing achieves the optimal dose more rapidly and provides superior clinical and laboratory benefits than traditional dosing strategies." | 2.94 | Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. ( Appiah-Kubi, AO; Creary, SE; Dong, M; Heeney, MM; Lane, A; Latham, TS; McGann, PT; Meier, ER; Nelson, SC; Niss, O; Pfeiffer, A; Piccone, C; Quarmyne, MO; Quinn, CT; Saving, KL; Scott, JP; Shook, LM; Talati, R; Vinks, AA, 2020) |
| "In the Stroke Prevention Trial for Sickle Cell Anemia Study, patients were randomized to receive long-term transfusion (CTX) or standard care (STC)." | 2.71 | Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. ( Adams, R; Brambilla, D; Morales, KH; Olivieri, N; Scher, CD; Styles, L; Wang, WC, 2005) |
| "Hydroxyurea (HDU) is a widely used medication for various malignancies, thalassemia, and sickle cell anemia with reported side effects." | 1.72 | Protective potential of royal jelly against hydroxyurea -induced hepatic injury in rats via antioxidant, anti-inflammatory, and anti-apoptosis properties. ( Abd-Ellatieff, H; El-Neweshy, MS; Ghamry, HI; Sayed, S; Shukry, M; Soliman, MM; Tohamy, HG, 2022) |
| "Hydroxyurea (HU) is a valuable therapy for individuals with sickle cell anemia." | 1.62 | Tolerability and age-dependent toxicokinetics following perinatal hydroxyurea treatment in Sprague Dawley rats. ( Black, SR; Fennell, TR; Fernando, RA; Huang, MC; Lu, Y; McIntyre, BS; Price, CJ; Robinson, VG; Ryan, KR; Silinski, MA; Turner, KJ; Vallant, M; Waidyanatha, S, 2021) |
| " Detailed examination of the lesion in animals dosed with 225C showed that there was a clear relationship between the onset of the lesion and the dose given, i." | 1.29 | Nephrotic syndrome associated with N-hydroxyureas, inhibitors of 5-lipoxygenase. ( Astbury, PJ; Evans, GO; Goodwin, DA; Read, NG; Rowlands, A, 1995) |
| "Zileuton pretreatment caused hepatomegaly and elevated liver peroxisomal KCN-insensitive palmitoyl CoA oxidase activity in a dose-dependent manner." | 1.29 | Hepatic peroxisomal and drug metabolizing activity in CD-1 mice after oral treatment with a novel 5-lipoxygenase inhibitor. ( Machinist, JM; Rodrigues, AD, 1996) |
| "Hydroxyurea (HU) is a potent teratogen that causes a characteristic, rapidly occurring episode of embryonic cell death 2 to 4 h after subcutaneously injecting 650 mg/kg of HU into pregnant New Zealand White rabbits on gestational day 12." | 1.28 | Ethoxyquin and nordihydroguaiaretic acid reduce hydroxyurea developmental toxicity. ( DeSesso, JM; Goeringer, GC, 1990) |
| "Timed-pregnant Fischer 344 rats were dosed by gavage with aniline hydrochloride (10, 30, or 100 mg/kg/day), a positive control agent (hydroxyurea, 200 mg/kg/day), or vehicle (distilled water) on gestational days (gd) 7 through 20 or gd 7 through parturition." | 1.27 | Teratologic and postnatal evaluation of aniline hydrochloride in the Fischer 344 rat. ( Ledoux, TA; Marks, TA; Paschke, LL; Price, CJ; Reel, JR; Tyl, RW, 1985) |
| "Hydroxyurea was administered intraperitoneally to pregnant albino rats in a single dose of 2000 mg/kg on day 14 of gestation." | 1.26 | Effects of hydroxyurea on postnatal growth and behaviour of rats. ( Fritz, H; Hess, R, 1980) |
| "Hydroxyurea was given to pregnant rhesus monkeys and pregnant rats in regimens adjusted to produce similar degrees of teratogenicity, for the purpose of comparing the distribution of the drug in the females and their embryos." | 1.25 | Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys. ( Fradkin, R; Ritter, EJ; Scott, WJ; Wilson, JG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (46.34) | 18.7374 |
| 1990's | 9 (21.95) | 18.2507 |
| 2000's | 7 (17.07) | 29.6817 |
| 2010's | 3 (7.32) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Easmon, J | 1 |
| Pürstinger, G | 1 |
| Heinisch, G | 1 |
| Roth, T | 1 |
| Fiebig, HH | 1 |
| Holzer, W | 1 |
| Jäger, W | 1 |
| Jenny, M | 1 |
| Hofmann, J | 1 |
| Tohamy, HG | 1 |
| El-Neweshy, MS | 1 |
| Soliman, MM | 1 |
| Sayed, S | 1 |
| Shukry, M | 1 |
| Ghamry, HI | 1 |
| Abd-Ellatieff, H | 1 |
| Huang, MC | 1 |
| Turner, KJ | 1 |
| Vallant, M | 1 |
| Robinson, VG | 1 |
| Lu, Y | 1 |
| Price, CJ | 2 |
| Fennell, TR | 1 |
| Silinski, MA | 1 |
| Waidyanatha, S | 1 |
| Ryan, KR | 1 |
| Black, SR | 1 |
| Fernando, RA | 1 |
| McIntyre, BS | 1 |
| Meier, ER | 1 |
| Creary, SE | 1 |
| Heeney, MM | 1 |
| Dong, M | 1 |
| Appiah-Kubi, AO | 1 |
| Nelson, SC | 1 |
| Niss, O | 1 |
| Piccone, C | 1 |
| Quarmyne, MO | 1 |
| Quinn, CT | 1 |
| Saving, KL | 1 |
| Scott, JP | 1 |
| Talati, R | 1 |
| Latham, TS | 1 |
| Pfeiffer, A | 1 |
| Shook, LM | 1 |
| Vinks, AA | 1 |
| Lane, A | 1 |
| McGann, PT | 1 |
| Singh, A | 1 |
| Chaudhary, R | 1 |
| Nityanand, S | 1 |
| Rana, S | 1 |
| Houston, PE | 1 |
| Wang, WC | 2 |
| Iyer, RV | 1 |
| Goldsmith, J | 1 |
| Casella, JF | 1 |
| Reed, CK | 1 |
| Rogers, ZR | 1 |
| Waclawiw, MA | 1 |
| Thompson, B | 1 |
| Pallio, G | 1 |
| Bitto, A | 1 |
| Pizzino, G | 1 |
| Galfo, F | 1 |
| Irrera, N | 1 |
| Minutoli, L | 1 |
| Arcoraci, V | 1 |
| Squadrito, G | 1 |
| Macrì, A | 1 |
| Squadrito, F | 1 |
| Altavilla, D | 1 |
| Thornburg, CD | 1 |
| Dixon, N | 1 |
| Burgett, S | 1 |
| Mortier, NA | 1 |
| Schultz, WH | 1 |
| Zimmerman, SA | 1 |
| Bonner, M | 1 |
| Hardy, KK | 1 |
| Calatroni, A | 1 |
| Ware, RE | 1 |
| Chahoud, I | 1 |
| Kuriyama, SN | 1 |
| Paumgartten, FJ | 1 |
| Akagi, T | 1 |
| Ushinohama, K | 1 |
| Kage, Y | 1 |
| Ishizaki, T | 1 |
| Makinosumi, T | 1 |
| Yamauchi, A | 1 |
| Taguchi, Y | 1 |
| Inoue, K | 1 |
| Yukawa, E | 1 |
| Higuchi, S | 1 |
| Ohdo, S | 1 |
| Mayhew, CN | 1 |
| Phillips, JD | 1 |
| Cibull, ML | 1 |
| Elford, HL | 1 |
| Gallicchio, VS | 1 |
| Chen, X | 1 |
| Wang, S | 1 |
| Wu, N | 1 |
| Sood, S | 1 |
| Wang, P | 1 |
| Jin, Z | 1 |
| Beer, DG | 1 |
| Giordano, TJ | 1 |
| Lin, Y | 1 |
| Shih, WC | 1 |
| Lubet, RA | 1 |
| Yang, CS | 1 |
| Morales, KH | 1 |
| Scher, CD | 1 |
| Styles, L | 1 |
| Olivieri, N | 1 |
| Adams, R | 1 |
| Brambilla, D | 1 |
| Kaplay, M | 1 |
| Prabhakar, V | 1 |
| Rao, KS | 1 |
| Fritz, H | 1 |
| Hess, R | 1 |
| Urna, G | 1 |
| Sardella, A | 1 |
| Denaro, MG | 1 |
| Cuzzocrea, M | 1 |
| Evenson, DP | 1 |
| Jost, LK | 1 |
| Read, NG | 1 |
| Astbury, PJ | 1 |
| Evans, GO | 1 |
| Goodwin, DA | 1 |
| Rowlands, A | 1 |
| Rodrigues, AD | 1 |
| Machinist, JM | 1 |
| Hackney, AC | 1 |
| Hezier, W | 1 |
| Gulledge, TP | 1 |
| Jones, S | 1 |
| Strayhorn, D | 1 |
| Busby, M | 1 |
| Hoffman, E | 1 |
| Orringer, EP | 1 |
| Korver, DR | 1 |
| Wakenell, P | 1 |
| Klasing, KC | 1 |
| Monte, MJ | 1 |
| El-Mir, MY | 1 |
| Sainz, GR | 1 |
| Bravo, P | 1 |
| Marin, JJ | 1 |
| Rioux, N | 1 |
| Castonguay, A | 1 |
| Shin, JH | 1 |
| Mori, C | 1 |
| Shiota, K | 1 |
| Cameron, IL | 1 |
| Rogers, W | 1 |
| Cohen, J | 1 |
| Woodhams, PL | 1 |
| Balázs, R | 1 |
| Dethlefsen, LA | 1 |
| Sorensen, SP | 1 |
| Riley, RM | 1 |
| Wilson, JG | 1 |
| Scott, WJ | 2 |
| Ritter, EJ | 2 |
| Fradkin, R | 1 |
| Adlard, BP | 1 |
| Dobbing, J | 1 |
| DeSesso, JM | 1 |
| Goeringer, GC | 1 |
| Asano, Y | 1 |
| Okaniwa, A | 1 |
| Kantarjian, HM | 1 |
| Smith, TL | 1 |
| McCredie, KB | 1 |
| Keating, MJ | 1 |
| Walters, RS | 1 |
| Talpaz, M | 1 |
| Hester, JP | 1 |
| Bligham, G | 1 |
| Gehan, E | 1 |
| Freireich, EJ | 1 |
| Tyl, RW | 1 |
| Marks, TA | 1 |
| Paschke, LL | 1 |
| Ledoux, TA | 1 |
| Reel, JR | 1 |
| Frankfurt, OS | 1 |
| Lea, MA | 1 |
| Sasovetz, D | 1 |
| Musella, A | 1 |
| Morris, HP | 1 |
| Butcher, RE | 1 |
| Kazmaier, K | 1 |
| Short, RD | 1 |
| Gibson, JE | 1 |
| Johanson, KJ | 1 |
| Rajewsky, MF | 1 |
| Fabricius, E | 1 |
| Hülser, DF | 1 |
| Klionsky, B | 1 |
| Wigglesworth, JS | 1 |
| Lerner, LJ | 1 |
| Bianchi, A | 1 |
| Yiacas, E | 1 |
| Borman, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxyurea Optimization Through Precision Study (HOPS): A Prospective, Multi-center, Randomized Trial of Personalized, Pharmacokinetics-guided Dosing of Hydroxyurea Versus Standard Weight-based Dosing for Children With Sickle Cell Anemia.[NCT03789591] | Phase 3 | 116 participants (Anticipated) | Interventional | 2019-01-17 | Recruiting | ||
| [NCT00000592] | Phase 3 | 0 participants | Interventional | 1994-07-31 | Completed | ||
| [NCT00006182] | Phase 3 | 0 participants | Interventional | 2000-07-31 | Completed | ||
| Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)[NCT00000586] | Phase 3 | 0 participants | Interventional | 1992-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for hydroxyurea and Body Weight
| Article | Year |
|---|---|
Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Body Weight; Bone Marrow Diseases; Child; Humans; Hydroxyu | 2020 |
Hydroxyurea and growth in young children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Body Size; Body Weight; Child, Preschool; Double-Blind Met | 2014 |
A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Body Height; Body Weight; Child, Preschool; Chronic Disease; Cognition; Drug To | 2009 |
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C | 2005 |
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C | 2005 |
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C | 2005 |
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C | 2005 |
Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Body Composition; Body Weight; Double-Blind Method; | 1997 |
36 other studies available for hydroxyurea and Body Weight
| Article | Year |
|---|---|
Synthesis, cytotoxicity, and antitumor activity of copper(II) and iron(II) complexes of (4)N-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines.
Topics: Antineoplastic Agents; Apoptosis; Body Weight; Burkitt Lymphoma; Carcinoma, Large Cell; Cell Cycle; | 2001 |
Protective potential of royal jelly against hydroxyurea -induced hepatic injury in rats via antioxidant, anti-inflammatory, and anti-apoptosis properties.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Body Weight; Caspase 3; Fatty Acids; Humans; Hydrox | 2022 |
Tolerability and age-dependent toxicokinetics following perinatal hydroxyurea treatment in Sprague Dawley rats.
Topics: Animals; Animals, Newborn; Antisickling Agents; Body Weight; Female; Hydroxyurea; Lactation; Male; P | 2021 |
Successful management of acute bleeding in essential thrombocythemia using automated cell separator.
Topics: Administration, Oral; Adolescent; Automation; Blood Platelets; Body Weight; Cell Separation; Female; | 2014 |
Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Body Weight; Catechin | 2016 |
Maternal protein-and-energy restriction reduces the developmental toxicity of cyclophosphamide and hydroxyurea in rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Body Weight; Cyclophosphamide; Di | 2002 |
Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Body Weight; Bone Marrow Cells; C | 2003 |
Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea.
Topics: Animals; Antiviral Agents; Benzamidines; Blood Cell Count; Body Weight; Bone Marrow; Hydroxamic Acid | 2002 |
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonat | 2004 |
Hydroxyurea inhibits thymidine kinase activity in developing rat cerebellum.
Topics: Animals; Body Weight; Cerebellum; DNA; Hydroxyurea; Kinetics; Nerve Tissue Proteins; Rats; Rats, Inb | 1983 |
Effects of hydroxyurea on postnatal growth and behaviour of rats.
Topics: Animals; Animals, Newborn; Body Weight; Brain; Female; Fertility; Fetus; Hydroxyurea; Male; Motor Ac | 1980 |
[Modifications in the feeding behavior of the rat, induced by antimitotic drugs: effects of hydroxyurea].
Topics: Animals; Body Weight; Feeding Behavior; Hydroxyurea; Male; Rats | 1980 |
Hydroxyurea exposure alters mouse testicular kinetics and sperm chromatin structure.
Topics: Animals; Body Weight; Chromatin; DNA; Flow Cytometry; Hydroxyurea; Male; Mice; Mice, Inbred C3H; Mic | 1993 |
Nephrotic syndrome associated with N-hydroxyureas, inhibitors of 5-lipoxygenase.
Topics: Administration, Oral; Animals; Blood Chemical Analysis; Body Weight; Chromatography, High Pressure L | 1995 |
Hepatic peroxisomal and drug metabolizing activity in CD-1 mice after oral treatment with a novel 5-lipoxygenase inhibitor.
Topics: Administration, Oral; Animals; Body Weight; Cytochrome P-450 Enzyme System; Dose-Response Relationsh | 1996 |
Dietary fish oil or lofrin, a 5-lipoxygenase inhibitor, decrease the growth-suppressing effects of coccidiosis in broiler chicks.
Topics: Aging; Analysis of Variance; Animals; Body Weight; Cecum; Chickens; Coccidiosis; Corn Oil; Dietary F | 1997 |
Bile acid secretion during synchronized rat liver regeneration.
Topics: Animals; Bile; Bile Acids and Salts; Body Weight; Cell Division; Enzyme Inhibitors; G1 Phase; Glycin | 1997 |
Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents.
Topics: Animals; Anticarcinogenic Agents; Arachidonic Acid; Aspirin; Body Weight; Carcinogens; Drug Screenin | 1998 |
Involvement of germ cell apoptosis in the induction of testicular toxicity following hydroxyurea treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Body Weight; DNA Fragmentation; Dose-Response Relationshi | 1999 |
Total intravenous hyperalimentation and hydroxyurea chemotherapy in hepatoma-bearing rats.
Topics: Animals; Body Weight; Carcinoma, Hepatocellular; Drinking; Eating; Hydroxyurea; Intestine, Small; Li | 1977 |
Preparation of viable astrocytes from the developing cerebellum.
Topics: Animals; Astrocytes; Body Weight; Cell Count; Cell Separation; Cells, Cultured; Cerebellum; DNA; Hyd | 1979 |
Effects of double and multiple doses of hydroxyurea on mouse duodenum and mammary tumors.
Topics: Animals; Body Weight; Cell Division; DNA; DNA, Neoplasm; Duodenum; Hydroxyurea; Kinetics; Mammary Ne | 1975 |
Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys.
Topics: Amniotic Fluid; Animals; Body Weight; Chorion; Embryo, Mammalian; Female; Gestational Age; Half-Life | 1975 |
Maze learning by adult rats after inhibition of neuronal multiplication in utero.
Topics: Animals; Body Weight; Brain; Cell Count; Female; Humans; Hydroxyurea; Learning; Learning Disabilitie | 1975 |
Ethoxyquin and nordihydroguaiaretic acid reduce hydroxyurea developmental toxicity.
Topics: Abnormalities, Drug-Induced; Animals; Antioxidants; Body Weight; Embryo, Mammalian; Ethoxyquin; Fema | 1990 |
In utero morphological effects of hydroxyurea on the fetal development in Sprague-Dawley rats.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Embryonic and Fetal Development; Female; Fetal De | 1987 |
Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Basophils; Blood Cell Coun | 1985 |
Teratologic and postnatal evaluation of aniline hydrochloride in the Fischer 344 rat.
Topics: Abnormalities, Drug-Induced; Aniline Compounds; Animals; Animals, Newborn; Blood; Body Weight; Eryth | 1985 |
Enhancement of the antitumor activity of 5-fluorouracil by drug combinations.
Topics: Animals; Body Weight; Carcinoma, Ehrlich Tumor; Cell Count; Floxuridine; Fluorouracil; Hydroxyurea; | 1973 |
Effects of hydroxyurea and 6-mercaptopurine on growth and some aspects of carbohydrate metabolism in regenerating and neoplastic liver.
Topics: Animals; Body Weight; Carcinoma, Hepatocellular; DNA; DNA, Neoplasm; Glucokinase; Glucose; Hepatecto | 1970 |
Postnatal effects in rats of prenatal treatment with hydroxyurea.
Topics: Abnormalities, Drug-Induced; Analysis of Variance; Animals; Behavior, Animal; Body Weight; Embryo, M | 1973 |
Biosynthesis of deoxyribonucleic acid, ribonucleic acid and protein in vivo by neonatal mice after a toxic dose of cyclophosphamide.
Topics: Animals; Animals, Newborn; Body Weight; Brain; Carbon Radioisotopes; Cyclophosphamide; DNA; Hydroxyu | 1973 |
Incorporation of 3 H-thymidine into deoxyribonucleic acid of mouse small intestine in vitro.
Topics: Age Factors; Animals; Body Weight; Chromatography, Ion Exchange; Culture Media; Culture Techniques; | 1972 |
Synchronisation in vivo: temporary inhibition of DNA synthesis in the rat embryo with hydroxyurea.
Topics: Animals; Body Weight; DNA; Female; Fetus; Gestational Age; Half-Life; Hydroxyurea; Injections, Intra | 1971 |
Production of experimental models of foetal growth retardation by inhibition of DNA or protein synthesis.
Topics: Analysis of Variance; Animals; Body Weight; Brain; Cycloheximide; DNA; Embryonic and Fetal Developme | 1970 |
Effects of hydroxyurea and related compounds on the blood and marrow of experimental animals.
Topics: Adrenal Glands; Animals; Antineoplastic Agents; Blood Cell Count; Blood Cells; Body Weight; Hydroxyu | 1966 |